AstraZeneca’s Lynparza medicine helped men with a lethal but uncommon form of prostate cancer in a study, opening a potential new use for a drug cleared for breast and ovarian cancers.
The medicine was successful in a final-stage test of metastatic castration-resistant prostate cancer. Patients’ tumors also had specific gene mutations and had failed to respond to other treatments, according to a statement from Astra and Merck & Co., its partner in developing the drug.
The study widens the potential uses for Lynparza, a drug that attacks tumors by thwarting the repair mechanisms of cells with certain gene flaws, rendering them unable to grow. The treatment, already used for breast cancer, has appeared promising in other malignancies, including a specific form of pancreatic cancer.
Analysts project about $1 billion in Lynparza sales for the year. Key to its prospects are the results of trial, due later this year, that tests the drug in a wide population of ovarian cancer patients, said Sam Fazeli, a Bloomberg Intelligence analyst.